Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nautilus Biotechnology Q3 2026 Results: Net Loss of $15.6M, Loss Widens

Nautilus Biotechnology reported total revenue of $424,000 for the nine months ended September 30, 2026, primarily from grant and service revenue, compared to zero revenue in the prior year. The company's total assets decreased from $191.1 million at the end of 2025 to $148.9 million as of September 30, 2026, driven by an accumulated deficit of $376.8 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.20.0
Net income-15.6-13.6
EPS (diluted, $ a share)$-0.12$-0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: NAUT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nautilus Biotechnology, Inc.: key numbers

Share price
$2.10Close, Nov 16
Market cap
$267M
Shares outstanding
127.37MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nautilus Biotechnology, Inc.

All →
6:01 AM ET 8-K
Financial Results

Nautilus Biotechnology Financial Results

Nautilus Biotechnology reported third quarter 2026 financial results, highlighting a net loss of $15.6 million on revenue of $0.2 million. The company noted progress on its proteoform assay pipeline and its Voyager platform, with plans for instrument availability in mid-2027. Subsequent to the quarter, the company was selected for an ARPA-H research consortium expected to provide up to $6 million in funding.

“The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform. Our seminal publication in Nature Methods highlights the unique biological insights that our technology can deliver. In addition, our proteoform expansion initiative is on-track, with early oncology assay results that demonstrate the performance we established with Tau is repeatable across additional targets. This repeatability is fundamental to our strategy of building a broad portfolio of proteoform assays, and the progress we are seeing reinforces our confidence in our technology, our development roadmap, and our planned instrument availability in the middle of 2027.”

Sujal Patel, CEO of Nautilus Biotechnology

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.